Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
MELBOURNE and ADELAIDE (Australia) – 30 October 2019. Telix announces collaboration and technology licensing agreement with AusHealth for novel MTR platform called APOMAB®
Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the treatment of ovarian and lung cancers.
The research behind the APOMAB® technology was led by Professor Michael Brown at the Royal Adelaide Hospital (RAH) with support from AusHealth Research, a division of AusHealth.
To read the full media release click here.